HyperRAB 300 IU/mL is a higher-potency formulation of a previously Food and Drug Administration–approved rabies immune globulin (RIG; human), HyperRAB S/D, also available as 1,500 IU/10 mL.1 The original HyperRAB S/D is available as 300 IU/2 mL and 1,500 IU/10 mL.
Administration and Dosing
RIG is administered as postexposure prophylaxis along with the rabies vaccine in people with suspected rabies exposure.2 RIG provides passive immunity until active immunity with the rabies vaccine is recognized. RIG should not be given to anyone who has been previously immunized with rabies vaccine and has a confirmed adequate rabies antibody titer. For unvaccinated people, the combination of rabies vaccine and RIG is recommended for bite and non-bite exposures, regardless of the time between exposure and postexposure prophylaxis initiation. Do not give RIG beyond day 7 after receiving the rabies vaccine because an antibody response to the vaccine is presumed to have already occurred.